Andrea I. Varga
Villejuif, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Journal: ESMO open
Published: December 18, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 05, 2024
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Journal: JCO precision oncology
Published: October 31, 2022
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.
Journal: Cancer discovery
Published: August 08, 2022
PALLIA 10 score in phase I cancer studies.
Journal: BMJ supportive & palliative care
Published: February 28, 2022
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 27, 2021
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Journal: Molecular cancer therapeutics
Published: July 30, 2021
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Journal: American journal of hematology
Published: April 20, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Journal: NPJ breast cancer
Published: October 08, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers.
Journal: Journal for immunotherapy of cancer
Published: March 21, 2020
Last Updated: 09/26/2026